Pressemeddelelse fra Jennewein Biotechnologie GmbH

• China represents the largest market for baby food globally
• Human milk oligosaccharides are key for the development of a healthy infant microbiome

"After already having introduced human milk oligosaccharides in other world regions, such as the key U.S. market and selected European countries, we are very excited to work with Yili, the domestic market leader for microbiome/baby food in China" statedDr. Stefan Jennewein, CEO and Co-Founder of JenneweinBiotechnologie. "With 50% of the total global market volume (2021e: 76 billion US$) China is presently the largest market for baby food. We are committed to bringing the benefits of human milk oligosaccharidesfor the development of a healthy infant microbiome to Chinese parents and their children."

Human milk oligosaccharides (HMOs) constitute the third largest component of breast milk and are unique to humans in concentration and structural diversity. HMOs possess several physiological effects; they confer protection against infectious diseases (e.g. noro viruses) and act as prebiotics for the development of the infant microbiome. Today, it is widely recognized that the establishment of a healthy microbiome is key for the overall development of an infant. Failure to support a natural or healthy microbiome may potentially lead to obesity, autism or allergy development in addition to other existing issues in infant health and development. However, most infant formulas do not contain HMOs as of today.

Dr GerritSmit, managing director of Yili Innovation Center Europe stated: "Yili Group has been dedicated to Chinese breast milk composition studies for years and has initiated the establishment of a Chinese Breast Milk Database. Yili has constantly brought innovative products to the market based on scientific research, for example Pro-Kido, and is looking forward to collaborating with Jennewein in the future."

About HMOs:

Human milk oligosaccharides (HMOs) are complex sugar molecules that are only present in breast milk. They are the third most abundant constituent of human milk after lipids and lactose. More than 200 structurally different HMOs have been identified. The most abundant HMO is 2′-fucosyllactose, which is produced by about 80% of all lactating mothers at concentrations of up to 2 g/L.Scientific studies have shown that HMOs, and 2′â??fucosyllactose in particular, have a positive impact on infant development. HMOs are prebiotic, i.e. they specifically promote the growth of beneficial microorganisms, and at the same time they inhibit the growth of pathogens. JenneweinBiotechnologie initially launched HMO 2′-fucosyllactose onto the global baby food market in 2015.

Kontakt:

Media Contact: Jennewein Biotechnologie Dr. Bettina Gutierrez bettina.gutierrez@jennewein-biotech.de 02224/98810797

Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/jennewein-biotechnologie-and-yili-group-join-forces-in-china-for-microbiome-research-and-human-milk-oligosaccharides-to-bring-innovation-to-the-largest-baby-food-market?releaseId=13567960